2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
The sponsor of Teucrium Commodity Trust said its Teucrium Wheat Fund (WEAT) may now invest in Kansas City Hard Red Winter wheat futures and Minneapolis Hard Red Spring wheat futures. The fund would use these alternatives only if position limits, accountability levels or price fluctuation limits on its benchmark wheat futures restrict its ability to hold the amounts it needs. The filing warns that these contracts may cause the fund's net asset value to track its benchmark less closely and that these markets are less liquid.
Change is effective immediately; the fund's investment objective, benchmark and benchmark component futures contracts are unchanged.
Alternative contracts are KC HRW Wheat futures on the Chicago Board of Trade and HRS Wheat futures on the Minneapolis Grain Exchange.
Allocation to alternatives is at the sponsor's sole discretion, with holdings in the same contract months as existing benchmark component positions.
A Rule 424(b)(3) prospectus supplement was filed August 31, 2026, to be read with the prospectus dated April 30, 2026.
Aprea Therapeutics announced an update to its intellectual property portfolio covering its precision oncology programs, citing 28 issued and 30 pending patents. The filing reports no financial results, and it does not describe any change in the company's clinical programs or financial position.
Company reports 28 issued and 30 pending patents across its programs.
WEE1 family of applications, if granted, would expire in 2047, excluding any regulatory exclusivities.
ATR inhibitor granted patents expire 2035-2037; pending applications could extend exclusivity into 2045.
Company is considering further development of ATRN-119 in combination therapies after completing dose escalation.
NeuroOne Medical Technologies announced that three large-animal procedures using its StereoCED platform were completed at the University of Minnesota as part of a preclinical epilepsy research program. The company says the procedures established technical feasibility, and it expects to recognize related animal-use revenue in fiscal Q4 2026 and plans a launch for human investigational studies later this quarter, though the filing gives no revenue amount and the platform is not approved for commercial use.
Three large-animal procedures completed at the University of Minnesota, announced August 27, 2026
In two of the three procedures, drug delivery electrodes delivered a study agent into targeted brain tissue and recorded electrophysiological activity from the same regions
Revenue from the animal-use devices is expected to be recognized in fiscal Q4 2026; no dollar amount is given
Human investigational device release is planned by the end of fiscal Q4 2026, with launch planned later this quarter
MBX Biosciences said it has dosed the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism. The trial is planned to enroll approximately 160 adults and is a step toward potential registration of the drug candidate, though the filing reports no financial results or regulatory approval.
First patient dosed in the Phase 3 oPTimize trial, announced August 27, 2026
Trial plans to enroll approximately 160 adults, randomized 3:1 to canvuparatide or placebo over a 26-week double-blind period
Primary endpoint is a composite responder measure at Week 26, followed by a 78-week open-label extension
Trial is registered as NCT07699471 on clinicaltrials.gov
Standard Nuclear said it executed a binding fuel supply agreement with Antares Nuclear, Inc., a developer of microreactors for defense and space applications. Under the agreement, the company will deliver a minimum of one MTU and up to eight MTUs of TRISO fuel through 2035. The filing does not disclose the contract's value, so its financial effect on shareholders cannot be sized from the document.
Binding fuel supply agreement announced August 27, 2026, with Antares Nuclear, Inc.
Standard Nuclear will deliver a minimum of one MTU and up to eight MTUs of TRISO fuel through 2035.
Antares will use the fuel to power its microreactors for defense and space applications.
Starting August 27, 2026, the Trust will value its shares and calculate net asset value using the FTSE Sui Index instead of the CME CF Sui-Dollar Reference Rate - New York Variant, after the sponsor's license with CF Benchmarks ends August 31, 2026. The filing also changes the timing of the sponsor fee, which will now be paid at least quarterly in arrears instead of weekly, and renames the Trust from 21Shares Sui ETF to 21Shares Sui Staking ETF; the company says the other revisions do not materially affect shareholders' rights.
FTSE Sui Index replaces the CME CF Sui-Dollar Reference Rate - New York Variant for NAV calculations beginning August 27, 2026
Benchmark Licensing Agreement with FTSE International Limited is dated August 20, 2026, with a one-year initial term that renews automatically
Sponsor Fee moves from weekly to at least quarterly payment in arrears, still payable in SUI, under Amendment No. 1 dated August 26, 2026
Trust renamed on August 25, 2026 via Certificate of Amendment; Second Amended and Restated Trust Agreement signed August 26, 2026
The trust's sponsor signed a licensing agreement with FTSE International for the FTSE Dogecoin Index, which will replace the CF Dogecoin-Dollar US Settlement Price Index used to value shares and calculate net asset value starting August 27, 2026. The trust also adopted a Third Amended and Restated Trust Agreement and an amendment changing the sponsor fee payment from weekly to at least quarterly, both payable in Dogecoin; the filing says the trust agreement changes do not materially impact shareholder rights.
Benchmark change: CF licensing agreement terminates effective August 31, 2026; FTSE Dogecoin Index used from August 27, 2026
FTSE license has a one-year initial term, renewing automatically for one-year periods unless terminated
Sponsor fee payment timing changed from weekly in arrears to at least quarterly in arrears, payable in Dogecoin
Filing states the trust agreement revisions are ministerial, technical or clarifying and do not materially impact shareholder rights
The fund's sponsor signed a licensing agreement with FTSE International for the FTSE Solana Index, which will replace the CME CF Solana-Dollar Reference Rate - New York Variant for valuing shares starting August 27, 2026. The filing also shows a fund name change, a restated trust agreement, and a change to quarterly-or-less frequent payment of the sponsor fee, which the filing says are not expected to materially affect holders' rights.
FTSE Solana Index replaces the CME CF benchmark for net asset value starting August 27, 2026, after the CF Benchmarks license terminates August 31, 2026
Licensing agreement dated August 20, 2026 has an expected one-year initial term with automatic one-year renewals
Sponsor fee payment changed from weekly in arrears to at least quarterly in arrears, payable in SOL
Trust renamed from 21Shares Solana ETF to 21Shares Solana Staking ETF on August 25, 2026
The trust's sponsor signed a licensing agreement with FTSE International for the FTSE Ethereum Index, which will replace the CME CF Ether-Dollar Reference Rate used to value the fund's shares and calculate net asset value starting August 27, 2026. The sponsor also amended its fee terms so the sponsor fee is paid at least quarterly instead of weekly, and the trust renamed itself and updated its trust agreement; the filing says none of these changes materially affect shareholder rights.
Benchmark change: FTSE Ethereum Index replaces the CME CF Ether-Dollar Reference Rate - New York Variant, effective August 27, 2026, after the CF Benchmarks license terminates August 31, 2026.
Licensing agreement dated August 20, 2026, with an expected one-year initial term that renews automatically for one-year periods unless terminated.
Sponsor fee payment changed from weekly in arrears to at least quarterly in arrears, payable in ether (Amendment No. 2, August 26, 2026).
Trust renamed from 21Shares Ethereum ETF to 21Shares Ethereum Staking ETF; Fourth Amended and Restated Trust Agreement entered August 26, 2026.
Lightbridge Corporation disclosed that the Idaho National Laboratory issued a press release on August 24, 2026 stating the company has been selected to participate in the U.S. Department of Energy's Nuclear Energy Launch Pad Program, administered by the National Reactor Innovation Center at INL. The filing contains no financial figures, so its direct effect on shareholders is not quantified.
Announcement made by Idaho National Laboratory in a press release dated August 24, 2026
Company selected to participate in the Nuclear Energy Launch Pad Program, a U.S. Department of Energy initiative
Program is administered by the National Reactor Innovation Center at INL; no dollar amounts disclosed in the filing
Bicara Therapeutics entered a sub-sublease with Wayfair LLC on August 21, 2026, for about 35,090 square feet of office space at 10 St. James Avenue, Boston, to serve as its new corporate headquarters. Base rent is $105,279 per month, payable nine months after the commencement date, which is the later of October 1, 2026 and full execution of a landlord consent.
Premises: approximately 35,090 square feet at 10 St. James Avenue, Boston, Massachusetts
Base rent of $105,279 per month, starting nine months after the commencement date
Security deposit of $210,540 paid at signing
Sublease term ends on the earlier of September 30, 2028 or earlier termination under its terms
CPS Technologies entered into a lease dated August 19, 2026, for about 80,000 square feet at 523 Pleasant Street in Attleboro, Massachusetts. The company plans to move its corporate offices, manufacturing and product development there from Norton, Massachusetts during 2027, with base rent starting December 1, 2027.
Lease term is twelve years and ten months from August 19, 2026, with a construction period through May 31, 2027 and six months of base-rent-free time through November 30, 2027.
Base rent is $85,000 per month for the first six months, then about $1.05 million for the following lease year, rising 3% annually thereafter.
The landlord, VMD Industrial II, LLC, will contribute up to $3.2 million toward qualifying improvements after the company spends at least $1.6 million, and the company must post a $510,000 security deposit.
Presidio Property Trust completed a five-year lease extension with Johns Hopkins University, its largest tenant, for the Bloomberg School of Public Health at its Baltimore property. The filing does not disclose rent or revenue figures, so the financial effect on shareholders cannot be gauged from this document.
Lease extension completed on August 20, 2026, extending the term to December 31, 2031
Johns Hopkins University occupies all 31,752 square feet of the Baltimore property
Chief Investment Officer Gary Katz said the company is pleased the property fits the tenant's long-term needs
Press release furnished under Item 7.01 and not deemed filed under Section 18 of the Exchange Act
Datacentrex said it has secured colocation space for more than 500 additional ElphaPex DG2 Scrypt ASIC miners, which it expects to energize within 30 days. The company says the miners were prepaid in 2025, so no additional capital will be spent on the units, and the filing reports no financial results for the period. For shareholders, the expansion would raise deployed hashrate by about 21%, but the filing gives no revenue, profit or cost figures to judge its financial effect.
More than 500 ElphaPex DG2 miners; delivery and energization expected within 30 days of August 24, 2026
Miners were prepaid in full in 2025; company says no additional capital will be deployed and cash is unaffected
Expected to add about 9.0 TH/s, raising deployed hashrate to about 52 TH/s, an increase of about 21%
Current fleet: 3,085 Scrypt ASIC miners, about 43.2 TH/s and 12.5 MW across four US colocation facilities
On August 24, 2026, Philip Morris International said certain of its non-U.S. affiliates have entered a contract manufacturing arrangement for combustible cigarettes with Philip Morris USA, an operating company of Altria Group. The company does not expect a material impact from the arrangement on its 2026 financials, and it says the deal does not change its plan to avoid commercializing combustible cigarettes in the United States.
Arrangement is between non-U.S. PMI affiliates and Philip Morris USA, an Altria operating company, announced August 24, 2026
First shipments are expected to begin early in 2027, subject to operational readiness and regulatory requirements
PMI does not expect a material impact on its 2026 financials
PMI has not commercialized combustible cigarettes in the U.S. and has no plans to do so
Precision BioSciences said it dosed the first patient in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD, a gene-editing treatment for Duchenne muscular dystrophy, at Arkansas Children's Hospital. The company said it expects to report initial safety data by year-end 2026. The filing reports no financial results, so it does not show a change in the company's financial position.
First patient dosed in August 2026 at Arkansas Children's Hospital
Study enrolls ambulatory DMD patients aged 2 to 7 with exon 45-55 mutations, which the company says cover up to 60% of boys with DMD
Company expects initial safety data by year-end 2026
Trial is registered as NCT07429240 on clinicaltrials.gov
Hinge Health entered an office lease on August 18, 2026 for about 119,278 rentable square feet at 300 Mission Street in San Francisco. Estimated base rent over the term is about $86.0 million, plus operating costs, and the lease is expected to expire February 28, 2037.
Estimated base rent over the lease term is about $86.0 million, plus the company's share of operating expenses, taxes and insurance
Landlord provides a tenant improvement allowance of up to $17.9 million
Company must post a $2.8 million irrevocable standby letter of credit to secure the lease
One five-year renewal option and a one-time early termination right effective January 31, 2035, subject to conditions including a termination payment
On August 14, 2026, Aptera Motors entered a Strategic Partnership Agreement with Shanghai Launch Automotive Technology under which Launch will provide manufacturing and contract-engineering work. Aptera agreed to pay up to RMB 300 million, with two-thirds of each approved invoice paid in cash up to RMB 200 million and one-third paid through warrants up to RMB 100 million. The filing says the deal could result in additional share issuance to Launch, which may dilute existing shareholders.
Agreement effective August 14, 2026; Launch to perform manufacturing, engineering, tooling and testing under agreed work orders
Initial warrants for 3,369,629 Class B shares, valued at RMB 50 million, issued to Launch on the effective date; not exercisable until credited against approved invoices
Warrants have a five-year term, with exercise prices of $2.20 for initial warrants and at least $2.25 per share for later warrants
Warrants are subject to a 4.99% beneficial ownership limit and a 19.99% exchange cap unless Nasdaq stockholder approval is obtained
Personalis received a new task order under its U.S. Department of Veterans Affairs contract for the Million Veteran Program, valued at up to $18.3 million and effective September 30, 2026. Cumulative task order value under the VA MVP contracts rose to approximately $243.3 million, though the order's value depends on receipt of samples and services performed.
New task order valued at up to $18.3 million, effective September 30, 2026
Task order is subject to receipt of VA MVP samples and performance of services by Personalis
Cumulative value of VA MVP task orders increased to approximately $243.3 million
UroGen Pharma's U.S. subsidiary obtained an exclusive option to license IntraGel Therapeutics' TumoCure product and hydrogel delivery platform for advanced head and neck cancer, plus options on additional products and a research license. The company also agreed to invest up to $7,000,000 in IntraGel's equity securities. The filing does not state financial terms of the option exercise or the size of any future payments.
Agreements dated August 18, 2026 with IntraGel Therapeutics, Ltd., an Israeli company
Exclusive option to obtain worldwide license to TumoCure with SRGel platform for advanced head and neck cancer
Agreed to invest up to $7,000,000 in IntraGel equity under a Securities Purchase Agreement
Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation (CKD) an exclusive license to develop and commercialize KIO-301 in South Korea for retinitis pigmentosa and other ophthalmology uses, under an agreement effective August 20, 2026. Kiora will receive a $1.0 million upfront payment, plus eligible milestone payments and double-digit royalties on South Korean net sales, and says the deal completes its global partner network for the product.
CKD pays a $1.0 million upfront payment to Kiora under the Exclusive License and Development Agreement.
Kiora is eligible for clinical, regulatory and sales milestone payments and double-digit royalties on net sales of KIO-301 in South Korea.
CKD will handle development and commercialization in South Korea; Kiora expects its partners Laboratoires Théa, Senju Pharmaceutical and CKD to run a single global Phase 3 trial.
The agreement was announced in a press release dated August 19, 2026, and either party may terminate it upon certain customary events.
Twist Bioscience disclosed that Anthropic, PBC published a blog post on August 18, 2026, saying it had received data from a protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview. Anthropic said it chose Twist as one of its independent evaluators to rapidly produce these AI-designed proteins at scale and test them for binding. The filing gives no financial terms, revenue figures, or contract value, so its effect on shareholders is not quantified.
Anthropic published a blog post on August 18, 2026 describing a multi-arm protein design campaign against 15 targets.
The campaign used Claude Opus 4.8 and Mythos Preview.
Anthropic named Twist Bioscience as one of its independent evaluators to produce and test AI-designed proteins for binding.
The filing is furnished under Item 7.01 and gives no financial figures for the arrangement.
Sezzle and WebBank entered into amended bank program agreements on August 12, 2026, adding two products, SezzleCash and Sezzle Send, to the existing loan program. For those two products WebBank will keep loans on its balance sheet up to an initial $30.0 million threshold, which it may raise to $150.0 million, and Sezzle's minimum tangible net worth requirement rises from $12.0 million to $100.0 million.
Agreements dated August 12, 2026 amend and restate the September 26, 2024 bank program agreements with WebBank.
WebBank will retain SezzleCash and Sezzle Send loans to maturity, with an initial retention threshold of $30.0 million, which WebBank may raise up to $150.0 million.
Minimum tangible net worth covenant increases from $12.0 million to $100.0 million; new termination events added for judgments, fines or penalties and financial covenant breaches.
Program term is unchanged and runs through September 27, 2029; full agreements to be filed with the Form 10-Q for the quarter ending September 30, 2026.
On August 18, 2026, Safe Pro Group announced a new subcontract and purchase order for its AI threat detection and mapping software in support of a U.S. Department of State program, valued at approximately $180,000. The filing gives no revenue, profit, or guidance figures, so the award's effect on the company's financial results cannot be measured from this document.
Award value is approximately $180,000.
Order includes five hardened GPU-powered laptops with Spotlight OnSight software and 3 years of annual software licensing and AI model upgrades.
Software is designed to detect explosive threats from drones and support demining in Ukraine; press release dated August 18, 2026 is Exhibit 99.1.
Amprius Technologies signed a Second Amendment to its Fremont, California industrial lease with Los Altos Fields, LLC on August 7, 2026. The amendment extends the lease, which had been set to expire June 30, 2027, by 84 months through June 30, 2034, and adds two five-year extension options. The company expects total future lease payments after the amendment to be about $10.5 million.
Lease extended 84 months, from July 1, 2027 through June 30, 2034
Expected total future lease payments after amendment: about $10.5 million
Two five-year extension options, with base rent subject to annual escalation
Agreement dated August 7, 2026; full text filed as Exhibit 10.1
On August 7, 2026, the Fidelity Ethereum Fund (FETH) signed custodial agreements with Anchorage Digital Bank NA and BitGo Bank & Trust, N.A., and amended its sponsor and trust agreements to allow staking of the fund's ether. The sponsor expects staking to start as soon as practicable after the registration statement takes effect, with the trust keeping 85% of staking rewards. Shareholders may receive quarterly cash distributions, but the trust may sell rewards or ether to fund them, which could affect its ether exposure and share price or net asset value.
August 7, 2026: trust entered custodial services agreements with Anchorage Digital Bank NA and BitGo Bank & Trust, N.A.
Trust retains 85% of staking rewards; remaining 15% is paid as fees shared among the sponsor, custodians and node operators.
Trust intends to make quarterly cash distributions of net staking income, which may require selling rewards or a portion of its ether.
Staking expected to start as soon as practicable after the Form S-3 registration statement becomes effective.
VanEck Digital Assets, acting for the VanEck BNB ETF, signed a Custodial Services Agreement on August 5, 2026 with BitGo Bank & Trust, which will act as a second custodian for the trust's BNB. The filing states the trust keeps ownership of its BNB and that BitGo will hold it separately from other customers' assets and will not lend or pledge it without authorization.
Agreement dated August 5, 2026 with BitGo Bank & Trust, National Association, a nationally chartered bank supervised by the Office of the Comptroller of the Currency
BitGo provides a custodial account for BNB, with deposits and withdrawals to public blockchain addresses as instructed by the trust
Trust retains all right, title and beneficial ownership of its BNB; BitGo may not lend, pledge or rehypothecate it except as authorized or required by law
Full agreement filed as Exhibit 10.1 to the Form 8-K
AbCellera said it will release top-line results from its Phase 2 trial of ABCL635, an antibody drug for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause, before the market opens on Monday, August 10, 2026. The company will also hold an investor conference call and webcast that morning at 4:30 a.m. Pacific Time. The filing contains no trial results, so the announcement itself does not yet show whether the drug worked, but the data will be a key test for the program's future.
Top-line Phase 2 data for ABCL635 to be released before market open on Monday, August 10, 2026
Investor conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET the same day
Trial (NCT07118891) is randomized, double-blind and placebo-controlled with approximately 80 postmenopausal women
Grayscale Investments Sponsors, LLC, sponsor of the Grayscale Sui Staking ETF, entered into Amendment No. 2 to the trust agreement on August 6, 2026, with trustee CSC Delaware Trust Company. The amendment requires the trust to convert staking consideration to cash at least quarterly and promptly distribute the net proceeds to shareholders. Shareholders may receive regular cash distributions, but the amounts depend on staking consideration actually received and cannot be predicted with certainty.
Amendment No. 2 is dated August 6, 2026, and is between the Sponsor and CSC Delaware Trust Company, the trustee.
The trust must convert staking consideration to cash no less often than quarterly and promptly distribute net proceeds to shareholders.
The trust currently intends monthly distributions, after the Staking Fee and other trust expenses; the sponsor may receive part of the staking consideration as payment for facilitating staking.
The trust intends to file a Rule 424(b)(3) prospectus supplement to update disclosure on the amendment.
Theriva Biologics said it dosed the first patient in VIRAGE2, a small Phase 2a proof-of-concept study of more frequent repeated dosing of VCN-01 in first-line metastatic pancreatic cancer patients. The study will enroll 6 evaluable patients at a single site in Spain, with enrollment expected to finish in H2 2026 and initial data expected by Q3 2027. The filing reports no revenue, earnings or financial results, and the study is not formally powered to assess clinical efficacy.
First patient dosed in VIRAGE2, announced August 6, 2026
Study planned for 6 evaluable patients at a single site in Spain
Enrollment expected to be completed in H2 2026; initial pharmacodynamic and safety data expected by Q3 2027
Results are intended to inform the VCN-01 dosing regimen for a possible future Phase 3 trial
AmperCap Acquisition Company amended its Administrative Services Agreement with its sponsor, AmperSPAC LLC, on July 31, 2026, changing the $5,000 monthly services fee to quarterly payments made in advance, effective July 1, 2026. The filing says any prepaid amount not yet accrued at termination will be refunded within five business days.
Services fee is up to $5,000 per month for office space, utilities and administrative support.
Under the amendment, the fee is paid quarterly in advance, in the first month of each calendar quarter, effective July 1, 2026.
Unaccrued prepaid amounts are to be refunded to the company within five business days of the Termination Date.
A10 Networks issued Microsoft a warrant on August 3, 2026, allowing Microsoft to buy up to 800,000 common shares at $0.01 per share. The warrant is tied to Microsoft's purchases of A10 products and services, so the shares vest only if purchase thresholds are met.
Warrant covers up to 800,000 shares at an exercise price of $0.01 per share
Two tranches of up to 400,000 shares each, tied to purchase measurement periods ending June 30, 2027 and June 30, 2028
Exercisable from January 1, 2028 (first tranche) and January 1, 2029 (second tranche), expiring August 3, 2036
Issued under a Section 4(a)(2) private placement exemption; the warrant also includes accelerated vesting on specified change of control transactions
Evolus Europe amended its December 20, 2023 license and distribution agreement with Symatese Aesthetics, adding Canada and Australia/New Zealand as territories and granting Evolus exclusive rights to commercialize the Estyme injectable hyaluronic acid gel line there. The filing gives Evolus payments of €920,000 upfront and up to an additional €1.38 million on regulatory approvals, with commercialization expected in 2028, so the financial commitment is modest and the effect on results depends on approvals and sales that are not yet quantified.
Upfront signing payments of €920,000, plus up to €1.38 million more on receipt of certain regulatory approvals
Initial term of 15 years for each new territory from first regulatory approval, with automatic five-year renewals
Symatese is responsible, at its expense, for development and regulatory work needed in the new territories
Commercialization in Canada, Australia and New Zealand is expected in 2028; the company cites a total addressable market of about $500 million annually for neurotoxins and dermal fillers in these markets
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.